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Introduction
 The prevalence of opiate dependency in the UK is estimated at 
1.1% (ages 15-54) with over 130,000 patients reported to be receiving 
clinical treatment for this disorder [1]. Though other substances are 
more commonly used, the most prevalent illicit drug associated with 
opioid dependence is heroin. In Scotland, prevalence is higher than 
the rest of the UK. It is estimated that there were 61,500 people, aged 
15-64 years, using opiates in 2012/13, reflecting 1.74% of the general 
population, an increase of 3% from 2009-10 [2]. Heroin dependence 
is associated with many harms, including premature deaths (usually 
from overdose), which have fluctuated around an upward trajectory 
over the last twenty years [1]. In 2015 there were 3674 deaths report-
ed in England and Wales-a record high [3]. In the same year there 
were 706 drug-related deaths in Scotland, 15% more than in 2014, 
with 86% of these potentially attributed to one or more opioids [4]. 
As well as the risk associated with the pharmacological properties of 
opioids, opioid users are more likely to experience comorbid physical 
and mental health problems which may impact on risk and recov-
ery potential [5]. Indeed, concern about Blood Borne Virus (BBV) 
infections in injecting drug users has driven the development of in-
terventions to reduce harm-including the increased access to Opioid 
Replacement Therapy (ORT). Drug use also carries a wide range of 
social consequences which may be positively influenced by engage-
ment in effective treatment [6]. Opioid misuse contributes significant-
ly to social exclusion with users experiencing high rates of home-
lessness, unemployment and imprisonment resulting from acquisitive 
crime or prostitution [1]. In this context, it has been estimated that 
annual costs associated with drug misuse in the UK could be as high 
as £21 billion in the UK [7]. 
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 Opioid Replacement Therapy (ORT) is the main UK treatment 
for opiate dependency. Both methadone and buprenorphine-based 
drugs are licensed for this purpose in the UK with over 25,000 peo-
ple prescribed in Scotland, mostly receiving methadone. Choice of 
ORT agent reflects historic guidance that methadone was the ‘first 
line’ recommendation if both were suitable. Now, evidence suggests 
that both are equally effective, although concerns regarding a high-
er risk of methadone overdose have been raised. Many factors, in-
cluding higher costs and time commitment to dispense buprenor-
phine-based products, however, may have affected their wider use 
in the UK. Clinicians require better evidence to inform their clinical 
decisions. This study considers a cohort of treatment-seeking opi-
ate-dependent individuals in a single health board area in Scotland, 
prescribed methadone or buprenorphine/naloxone ORT, comparing 
2-year retention rates with the costs of treatment delivery and health 
care utilization.
Methods
 We compared 62 patients receiving buprenorphine/naloxone (as 
Suboxone©) with 175 receiving methadone ORT (Total N=237). The 
health economic component reports only those for whom a complete 
dataset was available (n=212). Administrative NHS data was used to 
assess treatment retention and costs over a two year period. Costs 
included those associated with ORT delivery as well as broader 
healthcare utilization.
Results
 No statistically significant differences were found with respect to 
retention rates or healthcare costs though the Cost Effectiveness 
Plane (CEP) showed considerable uncertainty in these results im-
plying that retention may be greater in the methadone group.
Conclusion
 This study suggests that, when combining all treatment delivery 
and additional healthcare costs, buprenorphine/naloxone is broadly 
equivalent in cost effectiveness to methadone ORT when delivered 
in the NHS system. Retention rates over 2 years were also compara-
ble. These data may support the view that buprenorphine/naloxone 
represents a cost-neutral alternative ORT to that of methadone. 
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Choice of ORT agent
 For thirty years, treatment for illicit drug misuse has focused on 
reducing drug-related harms. Opioid Replacement Therapy (ORT), 
using the drugs methadone and buprenorphine, are effective treat-
ments that can reduce these harms [5]. Availability of ORT shows 
considerable variation across the UK [8]. Since the mid noughties, 
however, it has also been recognised that services should offer greater 
choice and personalised/tailored care to match an individual’s aspira-
tions and risks, with the aim of delivering an improved likelihood of 
progress and “recovery”. Clinically, this has proven a difficult balance 
to achieve-with some changes in the commissioning of treatment in 
England and Wales, aiming to encourage progress towards a drug-free 
lifestyle, potentially being associated with increases in drug-related 
risks and death [9]. The mainstay UK ORT drug-methadone mix-
ture-has also become a focus of concern with some commentators, ar-
guing that its pharmaceutical effects could reduce recovery potential 
[10]. Consequently, the selection of ORT drug has remained the focus 
of debate.
 Methadone ORT has been the most common UK treatment for 
opioid dependence since the 1980s and it is now estimated that some 
25,569 people are prescribed this treatment in Scotland [8]. At the turn 
of the millennium, after successful introduction in mainland Europe, 
pharmaceutical products based on the opioid agonist/antagonist agent 
buprenorphine were promoted as an alternative treatment in the UK 
[11]. Both agents have been associated with a range of positive health, 
social functioning and criminal justice outcomes. Overall, the accu-
mulated evidence is now felt to support the view that these treatments 
are equally effective [8,12]. Until recently, however, UK guidance, 
suggested a hierarchy of use-with methadone preferred if both were 
clinically indicated [13]. Reflecting the developing evidence-base, 
the most recent UK treatment guidance, however, has now put both 
agents on a more equal footing [5]. 
 But these treatments have key clinical differences in terms of pa-
tient-experience and delivery. Because of partial antagonist activity, 
buprenorphine induction presents clinical challenges and potential-
ly more early drop-outs [12]. Additionally, until recently, buprenor-
phine-based agents were available only as sub-lingual tablets that 
require longer pharmacy visits, increasing associated costs when su-
pervised dispensing is required. This may be one reason that, while 
the relative proportions fluctuate, buprenorphine prescribing remains 
less common than methadone [8]. Also, in urban community pharma-
cies, where there may be large numbers of patients receiving super-
vised ORT, the additional time commitment may limit access to ORT 
if sub-lingual buprenorphine-based products are preferred. 
 On the other hand, epidemiological studies in the UK have queried 
increased overdose risk associated with methadone prescribing when 
compared to buprenorphine [14]. As UK drug deaths are now a major 
concern, this phenomenon may be one reason that more recent na-
tional data has shown an increase in the proportion of buprenorphine 
prescribing in Scotland [8].
Health economic evaluations
 International studies have suggested that methadone ORT may 
deliver better retention than buprenorphine [15-18]. However, none 
was set in a UK treatment setting. Although evidence has shown 
methadone to be broadly less expensive to deliver than buprenor-
phine-based ORT, one UK health economic evaluation suggested that 
buprenorphine/naloxone was actually less costly than methadone. 
This study also found that, while methadone was associated with bet-
ter rates of 6 month retention in treatment, buprenorphine/naloxone 
was more likely to support achieving abstinence [19].
 There is little evidence on the difference in wider health care costs 
between ORT with methadone and any of the standard buprenor-
phine-based treatments (generic, Subutex© or Suboxone©). As more 
varied formulations of buprenorphine-such as depot preparations - 
have become available in the UK recently [20], more valid evidence 
is required to help direct clinical care delivery, ensuring that patients 
receive the most appropriate ORT.
Aims and objectives
This study aimed to:
1. Assess treatment and wider health care costs associated with 
methadone and buprenorphine/naloxone ORT;
2. Assess the relative rates of retention in treatment at two years;
3. Compare the cost-effectiveness of these drugs.
Methods
Sample
 In 2014, an audit sample had been derived from a communi-
ty-based National Health Service (NHS) addiction treatment ser-
vice in a Scottish region-NHS Fife Addiction Services (FAS). This 
sample comprised of 62 opiate-dependent ORT cases prescribed the 
buprenorphine/naloxone product Suboxone® and 175 who were pre-
scribed methadone. Representativeness of the study sample at base-
line was evaluated by comparing key characteristics with those of the 
total FAS treatment population. 
Data acquisition process 
 This study used patient-identifiable baseline data from a 2014 ser-
vice audit. These data were then linked, using unique identifiers, with 
a range of validated health informatics datasets describing prescribing 
information, clinical contacts and outcomes over the study period. In-
formatics techniques were then used to deliver an anonymised dataset 
to researchers for analysis. 
Datasets accessed
 The datasets utilised included: Locally compiled datasets, includ-
ing NHS Fife Addiction prescribing (FA); national datasets, includ-
ing: Community Prescribing (CP)-all prescribed medications by case; 
A&E attendances; out-patient attendances by service-SMR (Scottish 
Morbidity Record) 00; General Hospital admissions (SMR01); Psy-
chiatric Hospital admissions (SMR04) and General Register Office 
for Scotland (GROS) records for deaths.
Cost estimation
 A micro-costing exercise was conducted following the methods 
of technology appraisal recommended by the Scottish Medicines 
Council (SMC) [21]. Treatment costs included: Costs of the drugs 
themselves; dispensing fees (to pharmacists associated with dispens-
ing controlled drugs); instalment fees (relating to daily dispensing); 
supervision costs(relating to supervision responsibilities);and visits to 
the drug service (staff time). The financial year of 2012/13 was used 
for all unit costs. For costs occurring in the second year a discount rate 
of 3.5% was applied. Costs used are shown in table 1.
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 In order to cost the treatment, two datasets were combined: The 
NHS Fife Addiction (FA) and the Community Prescribing (CP) data. 
Start dates were chosen for each cohort member as the closest date 
in either file to October 2011. The NHS Fife Addiction (FA) dataset 
provided prescription cycles (28 days) as well as a record indicating 
when pharmacist supervision was required. However, as this local 
dataset was incomplete, the national Community Prescribing (CP) 
data was used to address any gaps. This CP dataset contained no indi-
cation of prescription cycles or supervision, and did not have accurate 
prescribing initiation dates (as in these records these were rounded 
up or down to the nearest month), but was used only to fill gaps in 
the FA data. Assumptions were made as to the presence of duplicated 
data based on the dates and doses recorded. In cases where it was not 
possible to tell if prescriptions were duplicates or not, the CP data was 
kept in the final combined dataset. Although this may lead to overes-
timating of the treatment costs overall, it kept the calculation method 
consistent across the two drug groups and ensured no underestimation 
of costs. The FA dataset was also found to contain some overlapping 
dates on prescription records. When identified, these records were as-
sessed by two clinicians in the study team who advised these anoma-
lies were likely due to changes in doses mid 28 day cycle (reflecting 
more urgent dose adjustments during this phase of treatment). The 
cycles were adjusted accordingly to reflect shorter cycles on different 
doses of the ORT drug. 
Treatment delivery costs
 The treatment was costed using cost per unit of drug, calculated 
from the Prescription Cost Analysis 2012/13, multiplied by the to-
tal dosage for each cycle [22]. The chemical name, dosage and form 
were used to calculate a weighted average. To each individual pre-
scription an average dispensing cost of £2.15 was then added [23]. 
Methadone (but not buprenorphine/naloxone) incurred an instalment 
cost of £1.79. FA data for that participant was used to estimate wheth-
er the prescriptions were supervised or not. The FA data, however, 
did not inform us on how many days the participant was supervised. 
Therefore, following expert clinical review (and reflecting local stan-
dard practice) it was agreed that we should normally assume 6/7 days 
supervision in a 28 day cycle. The CP data also had no recorded pre-
scription length, so we costed supervision/instalments by counting the 
number of days in a block of entries from the community data for 
either supervision or instalments. This pragmatic solution could be 
applied consistently throughout the whole dataset. Supervision costs 
were calculated from NHS Fife Pharmacy Services for the period 
2011 to 2013 with supervision costing £3.40 per visit for Suboxone© 
(the form of buprenorphine/naloxone used exclusively in the study 
area) and £1.40 for methadone.
 Regarding service attendances, the FAS standard was that an ORT 
patient would be seen at clinic on a monthly basis-whatever drug was 
prescribed. Additional visits may be organised at times of higher risk, 
when contact may be escalated. We therefore costed one monthly visit 
with a nurse as the minimum that would have occurred. This was cost-
ed using the average nurse-led outpatient clinic visit unit cost (£60), 
since no specific drug service costs were available. 
Healthcare resource utilization
 In order to cost the 2 year healthcare resource use, a predicted end 
date was generated for each participant by adding 730 days to their 
start date. The administrative files were then filtered using the start 
and predicted end date. Any NHS resource use within this period was 
then costed (with the second year discounted at 3.5%). For baseline 
adjustment, the six month period before the participants’ start date 
was also costed. 
Out-patient clinic attendances: Outpatient visits at the addiction 
service were categorised as either a consultant or nurse-led clinic and 
then separated into different specialities. The costs book, compiled 
by ISD, was applied using clinic type and speciality [23]. Within the 
outpatient data, some visits were classed as Did Not Attend (DNA), 
with no prior warning. For this we costed full amount, assuming staff 
time could not be reallocated.
Hospital attendances: For A&E attendances, visits were costed us-
ing the cost book giving an average unit cost for an attendance at 
A&E. Ambulance transport incurred an additional cost. Any subse-
quent hospital admission was costed within the inpatient data. Inpa-
tient data was split into three categories: Inpatient days, day cases 
and inpatient days-less than one (representing a short stay). These 
were then costed by speciality. For inpatient days - more than one, 
the cost per bed day was multiplied by the number of days. For day 
cases, a cost per case was applied. For those inpatient days - less than 
one, the one day cost was applied as a conservative estimate, since no 
standard short stay costs were available [24]. The cost per speciality 
came from patient-level data (including procedures) acquired from 
NHS Scotland [25].
Outcome measure
 Our primary outcome measure was 2 year retention in treatment. 
If the participant had a gap greater than 28 days at any point, they 
were considered not retained and treatment data was not costed from 
then. If the treatment duration was less than two years by more than 
28 days, they were also considered not retained. 
Cost-Effectiveness Analysis (CEA)
 Incremental cost-effectiveness analysis was performed to combine 
the identified costs with the outcome. Where applicable a Cost-Effec-
tiveness Ratio (ICER) was calculated. The mean difference in costs 
between the two groups was compared with the mean difference in 
effectiveness. The below formula is for the ICER, whereby ∆ rep-
resents difference, E represents effects, C represents the cost of the 
intervention, while subscripts ‘I’ and ‘UC’ refer to intervention and 
usual care, respectively. 
 If, however, one treatment was both more effective and less costly, 
this treatment was said to be ‘dominant’ and an ICER deemed unnec-
essary. 
Treatment Unit Cost Reference
Methadone Buprenorphine/Naloxone
Dispensing fee £2.15 £2.15 (ISD Scotland 2012/13)
Instalment fee £1.79 - Recorded by study
Supervision fee £1.40 £3.40 Recorded by study
Drug service visit £60.00 £60.00 (ISD Scotland 2012/13)
Table 1: Unit costs of treatment.
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Handling uncertainty
 The non-parametric bootstrap re-sampling technique was em-
ployed to explore the sensitivity of calculated costs and effect [26]. 
Cost and outcome data were bootstrapped to account for skewness, 
sampling with replacement and observation 5000 times to generate a 
new population of sample means with an approximate normal distri-
bution. These bootstrap results were then displayed graphically using 
a Cost-Effectiveness Plane (CEP) to show the uncertainty surround-
ing the mean estimates of incremental costs and effects. 
Sensitivity analysis 
 In addition to the primary analysis, a sensitivity analysis was un-
dertaken to repeat the cost-effectiveness using mean imputation for 
missing variables. Since there were 19 participants who crossed over 
to another treatment during the study period, a sensitivity analysis 
excluding these participants was also conducted. Once more, the out-
liers for wider health care resource use at baseline were explored and 
those more than three times the group standard deviation were ex-
cluded from the analysis. 
Information and research governance
 Standard operating procedures at HIC Services, University of 
Dundee, were followed to ensure anonymization of the dataset. HIC 
Services is a University of Dundee/NHS research support unit within 
the Tayside Medical Science Centre (TASC). It operates a secure “safe 
haven” environment with robust data governance for the provisioning 
of clinical data to academics for research (http://medicine.dundee.
ac.uk/hic). Relevant permissions were obtained prior at the inception 
of the 2014 audit as was NHS Research and Development (R&D) per-
mission - obtained through NHS Research Scotland (NRS). Ethical 
approval was obtained from the East of Scotland Ethics Committee. 
The Fife Caldicott Guardian granted permission to access NHS Fife 
electronic extractions. Updated permissions were subsequently ob-
tained for the 2 year follow up study. 
Results
Representativeness of sample
 The study population was found to be representative of FAS total 
population with regard to age, gender profile and stability of housing. 
There were significant differences, however, regarding employment 
status at baseline, with high rates of unemployment observed in the 
study sample population (92%) compared to the overall FAS pop-
ulation (81%). This reflected particularly high levels of unemploy-
ment in the study methadone group (99%) while the buprenorphine/
naloxone group had a lower unemployment rate (79%). Also, while 
self-reported mean heroin use in the study sample was representative 
of the FAS population as a whole, the proportion reporting injecting 
was significantly higher in the sample population (11%) than in the 
FAS total population (4%). The study sample therefore had higher 
levels of unemployment and intravenous drug use when compared to 
the total service population, reflecting significantly higher rates in the 
methadone treated sample.
Exclusions
 Of the 244 participants included at study inception (FAS audit), 
three were excluded from this analysis. One was missing from the 
FA dataset; one had conflicting data in the CP and FA dataset; one 
was represented in both the buprenorphine/naloxone and methadone 
cohorts. Of the remaining 241 participants, 29(12%) were missing 
other key data and so were excluded. Subsequently, 212 participants 
were included within the basecase analysis. The baseline characteris-
tics following this exercise are shown in table 2.
 Comparison of baseline characteristics following these exclusions 
showed that buprenorphine/naloxone and methadone groups did not 
differ by age (t-test: p=0.522), gender (χ2test: p=0.474) in the base-
case, nor in the mean imputation analysis (Table 2). Figure 1 reports 
the scores at baseline for both groups and analyses using the Scottish 
Index of Multiple Deprivation [27], which is divided into quintiles 
from 1 (most deprived) to 5 (least deprived). There were no statis-
tically significant differences between groups in the basecase analy-
sis (ANOVA: p=0.224) nor the mean imputation analysis (ANOVA: 
p=0.130).
Outcome-retention in treatment
 One participant in the buprenorphine/naloxone group successfully 
completed treatment before the two-year study period, indicated by a 
recorded change in medication to the opioid blocker Naltrexone. This 
participant was therefore inputted as retained. Those that died during 
treatment were inputted as not retained. Some 57% of buprenorphine/
naloxone and 69% of methadone cases were retained. The adjusted 
difference was calculated using a logistic regression as the outcome 
was binomial and is reported as an odds ratio. This difference was 
not statistically significant in the basecase analysis [OR=0.64 (95% 
CI=0.34 to 1.21, p=0.171)] nor the mean imputation sensitivity anal-
ysis [OR=0.58 (95% CI=0.31 to 1.05, p=0.073)].
Treatment delivery costs
 Costs reflected drug cost, dispensing fees, instalment cost and 
supervision fee where applicable as well as costs associated with a 
monthly drug service review visit. The basecase analysis revealed 
the buprenorphine/naloxone group had a greater number of dis-
pensed items, but was subject to significantly less supervision (T-test: 
p<0.001). Although the buprenorphine/naloxone group did not in-
cur an instalment cost, some participants crossed over to methadone 
during the study, incurring instalment costs in 30 cases. Service atten-
dances were the same for both groups. The mean imputation analy-
sis revealed similar results to the basecase. The mean treatment costs 
of the two groups were compared using a Generalised Linear Model 
(GLM) with a gamma distribution (Table 3).
Figure 1: Baseline deprivation scores by treatment group.
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 The adjusted difference in mean total treatment costs was £918 
greater for buprenorphine/naloxone, driven by the mean cost of the 
drug formulation (Suboxone©). This difference was statistically sig-
nificant. The mean imputation analysis results showed buprenorphine/
naloxone treatment costs to be £854 greater than for those with meth-
adone. Again this difference was statistically significant (p<0.001). 
Wider health care costs
 Regarding use of healthcare services, participants prescribed bu-
prenorphine/naloxone were found to have fewer A&E attendances 
(0.9 vs. 1.7); fewer acute hospital inpatient days (0.4 vs. 1.4) and 
psychiatric hospital inpatients days (0.481.3 vs. 1.30.48); the same 
number of outpatient visits (2.6 vs. 2.6) and more day case attendanc-
es (0.2 vs. 0.0). The most widely used outpatient facility was for men-
tal illness and the most widely used inpatient facility was for acute 
medicine. For buprenorphine/naloxone, 26% and for methadone 33% 
of outpatient visits were recorded as DNAs. The mean imputation 
analysis showed very similar results to that of the basecase, with just 
marginally greater inpatient days and psychiatric days for the meth-
adone group. The associated wider health care costs are presented in 
table 4. Total health care costs were -£1258 (95% CI=-£2502 to -£13, 
p=0.048) lower for the buprenorphine/naloxone group after adjusting 
for baseline costs and characteristics. The mean imputation analy-
sis did not reach statistical significance with the adjusted regression 
(p=0.197).
Total costs
 Total costs of treatment delivery and healthcare utilization are 
summarised in table 5. The primary analysis results showed no sta-
tistically significant differences in costs between the methadone or 
buprenorphine/naloxone ORT groups. 
Cost-effectiveness analysis and uncertainty
 The degree of uncertainty relating to any differences is reflect-
ed in the Cost-Effectiveness Plane (CEP) presented in figure 2. This 
cost-effectiveness scatter plot was produced from the bootstrapping 
results for the difference in retention (presented as an odds ratio) and 
difference in cost. The results of the 5000 re samples were plotted 
on a cost-effectiveness plane, visually displaying any uncertainty 
surrounding the mean differences in costs and retention between bu-
prenorphine/naloxone and methadone. The majority of the plots are 
concentrated in the bottom right and bottom left quadrants, suggest-
ing there was considerable uncertainty about which treatment was 
less costly. The finding that there are fewer results in the northern 
quadrants may imply that methadone is more effective at retaining 
participants. Through bootstrapping the results, 95% confidence in-
tervals were also generated for both incremental cost and retention. 
The results were an incremental cost of-£121 (bootstrapped 95% CI=-
£1498 to £1053) and retention odds ratio of 0.64 (bootstrapped 95% 
CI=-0.33 to 1.29).
Basecase Mean Imputation
Methadone (n=154) (SD) Buprenorphine/ Naloxone (n=57) (SD) p-value Methadone (n=179) (SD) Buprenorphine/ Naloxone (n=61) (SD) p-value
Age 36 (8) 37 (10) 0.5217 36 (8) 37 (10) 0.5694
% Female 35% 30% 0.474 34% 31% 0.675
Basecase Mean Imputation
Methadone (n=154) (SD) Buprenorphine/ Naloxone (n=57) (SD) Methadone (n=179) (SD) Buprenorphine/ Naloxone (n=61) (SD)
Pharmaceuticals £425 (£324) £2381 (£1500) £426 (£324) £2382 (£1501)
Dispensing £1337 (£348) £1373 (£273) £1337 (£352) £1348 (£298)
Instalments £1113 (£322) £52 (£207) £1106 (£331) £49 (£200)
Supervisions £405 (£308) £356 (£554) £427 (£331) £401 (£596)
Visits £1337 (£361) £1327 (£298) £1343 (£353) £1327 (£298)
Total £4612 (£1212) £5552 (£1819) £4639 (£1256) £5507 (£1848)
Adjusted difference (95% CI)
£918 (£406 to £1430) £854 (£361 to £1347)
p<0.001 p=0.001
Unadjusted difference (95% CI)
£938 (£432 to £1446) £868 (£372 to £1364)
p<0.001 P=0.001
Table 2: Baseline characteristics.
Table 3: Summary of mean treatment costs.
Note: *GLM model adjusted for age, sex and deprivation score (baseline characteristics).
Figure 2: Cost Effectiveness Plane (CEP).
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Sensitivity analysis
 Sensitivity analyses were carried out to test the robustness of the 
results. This included: Excluding the 19 participants who crossed to 
the other ORT treatment during the follow up period; excluding outli-
ers in terms of health care costs at baseline and excluding those who 
died during the study. Regarding cross over, more Suboxone© par-
ticipants (10 cases-18% of sample) crossed over than Methadone (9 
cases-6%) and their mean age was slightly lower than the average of 
the whole group at baseline. The percentage of females was similar 
in both groups (50% Suboxone, 44% methadone). Their SIMD scores 
are reported in figure 3.
 Results are shown in table 6. Excluding crossovers had little ef-
fect on the headline results, with slightly higher cost difference -£434 
in favor of Suboxone© (95% CI=-£2134 to £1265), and marginally 
less difference in retention, with those in the Methadone group 1.49 
times more likely to be retained. Excluding healthcare cost outliers at 
baseline (those greater than three times the standard deviation of the 
whole group) and the four deaths (all in the methadone group) also 
had little effect. All sensitivity analyses gave non-statistically signif-
icant results, highlighting further the uncertainty surrounding these 
findings.
Discussion
 Opiate dependency is prevalent in the UK with drug related death 
a common and increasing concern [3,4]. Engaging and retaining peo-
ple in treatment are vital and Opioid Replacement Therapy (ORT) is 
effective at achieving this goal [5]. Both methadone and buprenor-
phine (the agents currently licensed for ORT in the UK) are effec-
tive drugs [12]. In the UK, however, buprenorphine-based ORT has 
remained less popular for many reasons [8]. Little research of rele-
vance to the UK has explored cost-effectiveness differentials between 
buprenorphine and methadone. If buprenorphine-based ORT is found 
to be as effective as methadone (as systematic reviews suggest) and 
also brings potential to reduce drug deaths, then it is important that we 
understand potential barriers to its more widespread use.
Basecase Mean Imputation
Methadone (n=154) (SD) Buprenorphine/ Naloxone (n=57) (SD) Methadone (n=179) (SD) Buprenorphine/ Naloxone (n=61) (SD)
Outpatient cost £368 (£611) £397 (£825) £356 (£587) £397 (£801)
A&E cost £381 (£559) £161 (£350) £383 (£547) £160 (£468)
Inpatient cost £1330 (£4476) £466 (£1650) £1652 (£6991) £445 (£1620)
Psychiatric hospital cost £547 (£3173) £201 (£1410) £917 (£5994) £202 (£1365)
Community prescribing cost £513 (£725) £728 (£1261) £501 (£695) £730 (£1248)
Total £3147 (£5766) £1956 (£3103) £3811 (£9934) £1935 (£3008)
*Adjusted Difference (95% CI)
-£1258 (-£2502 to -£13) -£1207 (-£3039 to £625)
p-value=0.048 p-value=0.197
**Unadjusted Difference (95% CI)
-£1383 (-£2617 to -£148) -£1570 (-£2869 to -£272)
p-value=0.018
Basecase Mean Imputation
Methadone (n=154) (SD) Buprenorphine/ Naloxone (n=57) (SD) Methadone (n=179) (SD) Buprenorphine/ Naloxone (n=61) (SD)
Treatment £4612 (£1212) £5552 (£1819) £4639 (£1256) £5507 (£1848)
Healthcare £3147 (£5767) £1956 (£3103) £3811 (£9934) £1935 (£3008)
Total £7760 (£5875) £7508 (£3631) £8450 (£9828) £7443 (£3579)
*Adjusted Difference
£-121 (-£1341 to £1098) -£697 (-£1957 to £581)
p=0.846 p=0.285
**Unadjusted Difference
£-257 (-£1580 to £1067) -£894 (-£2429 to £641)
p=0.704 p=0.254
Table 4: Wider health care costs.
Note: *GLM model adjusted for baseline cost/characteristics; **GLM model adjusted for baseline cost.
Table 5: Cost per participant during two year study period.
Note: *GLM model adjusted for baseline cost/characteristics; **GLM model adjusted for baseline cost.
Figure 3: Crossover deprivation scores.
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 Using informatics techniques, we have compared patients on 
methadone and buprenorphine/naloxone (as Suboxone©) ORT over 
two years and have assessed the ability of both agents to retain people 
in treatment. We have assessed the cost associated with delivering this 
treatment and have also considered broader healthcare costs incurred, 
reflecting these patients’ use of NHS services. A Health Economic 
Analysis has been undertaken to determine which ORT agent is most 
cost effective at delivering retention in treatment.
 We found no statistically significant difference in cost effective-
ness between methadone and buprenorphine/naloxone ORT with re-
gard to retention in treatment at 2 years. There was, however, consid-
erable uncertainty in these results with the Cost Effectiveness Plane 
(CEP) showing most points below the line.
 The biggest driver of cost for buprenorphine/naloxone was the 
total treatment cost, which, at £918 (95% CI=£406 to £1430) was 
more costly than methadone and statistically significant (p<0.001). 
This finding is unsurprising due to the much higher pharmaceutical 
costs of the form of drug used in the study region during the study 
period-Suboxone©. The greatest driver of cost for methadone, how-
ever, was that of inpatient hospital care, reflecting greater healthcare 
utilisation- potentially reflecting less reduction in harms-in this group. 
Strengths and weaknesses of the study
 This study has used informatics techniques to create an anony-
mised dataset, giving us access to data not otherwise available for 
research purposes. This has allowed a more detailed assessment of the 
factors that may influence clinical decision making. However, there 
are many weaknesses in this study. 
 One weakness is the potential bias in the creation of the origi-
nal audit sample. The statistically significant difference between the 
groups at baseline in terms of deprivation status and living conditions 
suggests they may reflect patient groups whose dependency is at a 
different stage of development associated with different degrees of 
harm. The buprenorphine/naloxone sample consisted of all patients 
prescribed the drug at the index date. The methadone group, however, 
was opportunistically recruited over a similar time period from a larg-
er population on methadone ORT in the same Scottish region. The de-
mographic analysis showed the methadone group to be living in more 
urban environments and more deprived areas at baseline. This feature 
alone could have driven some of the differences in “cost” as the more 
deprived group may be more likely to require to access healthcare 
[28]. The groups may also have already been “selected” and matched 
to each treatment in the fife service-as many services report using 
buprenorphine-based ORT in patients who are more stable or are felt 
to have more recovery potential. We have not been able to determine 
whether this difference may further skew our results and conclusions. 
Finally, the study did not use a randomised sample and we cannot 
therefore remove the potential effects of confounders. 
 As reflected in the methods section, many assumptions were made 
due to the quality and complexity of the available, routinely-collected, 
administrative data used. Regarding the costs, the greatest uncertainty 
lay with the combining of the two prescribing datasets. It would be 
beneficial in future to improve the quality assurance of the NHS Fife 
Addiction dataset, so that this one dataset-with richer data - can be 
used for research purposes. The costs we used in the analysis includ-
ed the use of administrative data (the Scottish Morbidity Record or 
SMR). These data are not collected for research purposes and, though 
they contain valuable information, recorded by clinicians and admin-
istrators, they inevitably bring further uncertainty. Non-NHS costs – 
such as social care or criminal justice costs - were not included within 
this analysis as the data available were not sufficient to give accurate 
estimates of these wider societal costs, all of which are affected by 
substance use. This information would have strengthened the analysis 
considerably.
 Regarding outcomes, it has been argued that retention is a valuable 
“proxy” measure of clinical outcomes – as it is strongly associated 
with the clinical goals of reduced risk-taking, less drug use and im-
proved health and social functioning. As such, retention can be a help-
ful indicator of successful treatment and has been reported as such in 
numerous previous publications. However, in this study, there were 
no data available to examine those who were not retained. Instead ex-
pert clinical advice was sought and it was felt most prudent to assume 
that any participants leaving treatment before the two year end point 
should be classed as “not retained”. One participant who stopped 
ORT but started naltrexone before leaving the treatment service had 
objectively achieved abstinence so was classed as “retained”. 
 The overall uncertainty around our findings is a concern. These 
issues would benefit from further investigation, such as through a 
well-designed prospective Randomised Controlled Trial (RCT) using 
a more robust outcome measure such as Quality Adjusted Life Years 
(QALYs) [29]. QALYs is a generic health outcome measure that can 
be compared across all intervention types and is recommended in the 
UK by NICE and SMC for economic evaluations aiming to advice on 
cost-effectiveness. An RCT may also help to explore further the wider 
healthcare costs associated with ORT in a more robust fashion. 
 This study has shown how real life data extraction can be used in 
an economic evaluation of treatment for opioid dependency and that 
buprenorphine-based ORT remains a viable alternative to methadone 
in a UK community treatment setting. In the context of increasing 
drug death in the UK, more well-designed prospective studies, using 
robust data, are required to aid clinical decision-making and improve 
patient choice.
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Adjusted Difference in Retention (95% CI) p-value Adjusted Difference in Cost (95% CI) p-value
Excluding crossovers 0.67 (0.34 to 1.34) 0.26 -£434 (-£2134 to £1265) 0.616
Excluding outliers at baseline 0.72 (0.37 to 1.375) 0.316 -£327 (-£1938 to £285) 0.691
Excluding deaths 0.59 (0.30 to 1.12) 0.105 -£40 (-£1382 to £1302) 0.624
Table 6: Sensitivity analysis.
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